123 related articles for article (PubMed ID: 30576938)
1. Application of a discrete choice experiment approach to support the design of a hepatitis C testing service in primary care.
Radley A; van der Pol M; Dillon JF
Int J Drug Policy; 2019 Mar; 65():1-7. PubMed ID: 30576938
[TBL] [Abstract][Full Text] [Related]
2. Clinical effectiveness of pharmacy-led versus conventionally delivered antiviral treatment for hepatitis C in patients receiving opioid substitution therapy: a study protocol for a pragmatic cluster randomised trial.
Radley A; de Bruin M; Inglis SK; Donnan PT; Dillon JF
BMJ Open; 2018 Dec; 8(12):e021443. PubMed ID: 30552244
[TBL] [Abstract][Full Text] [Related]
3. Patient preferences for community pharmacy asthma services: a discrete choice experiment.
Naik-Panvelkar P; Armour C; Rose JM; Saini B
Pharmacoeconomics; 2012 Oct; 30(10):961-76. PubMed ID: 22823521
[TBL] [Abstract][Full Text] [Related]
4. Clinical effectiveness of pharmacist-led versus conventionally delivered antiviral treatment for hepatitis C virus in patients receiving opioid substitution therapy: a pragmatic, cluster-randomised trial.
Radley A; de Bruin M; Inglis SK; Donnan PT; Hapca A; Barclay ST; Fraser A; Dillon JF
Lancet Gastroenterol Hepatol; 2020 Sep; 5(9):809-818. PubMed ID: 32526210
[TBL] [Abstract][Full Text] [Related]
5. Factors influencing pharmacy services in opioid substitution treatment.
Chaar BB; Wang H; Day CA; Hanrahan JR; Winstock AR; Fois R
Drug Alcohol Rev; 2013 Jul; 32(4):426-34. PubMed ID: 23442133
[TBL] [Abstract][Full Text] [Related]
6.
Byrne C; Radley A; Inglis SK; Beer LJZ; Palmer N; Pham MD; Healy B; Doyle JS; Donnan P; Dillon JF
BMJ Open; 2020 Aug; 10(8):e036501. PubMed ID: 32868356
[TBL] [Abstract][Full Text] [Related]
7. DOT-C: A cluster randomised feasibility trial evaluating directly observed anti-HCV therapy in a population receiving opioid substitute therapy from community pharmacy.
Radley A; Tait J; Dillon JF
Int J Drug Policy; 2017 Sep; 47():126-136. PubMed ID: 28647161
[TBL] [Abstract][Full Text] [Related]
8. Managing Minor Ailments; The Public's Preferences for Attributes of Community Pharmacies. A Discrete Choice Experiment.
Porteous T; Ryan M; Bond C; Watson M; Watson V
PLoS One; 2016; 11(3):e0152257. PubMed ID: 27031588
[TBL] [Abstract][Full Text] [Related]
9. The Potential Reach of Opioid Substitution Settings to Deliver HCV Care to People Who Inject Drugs in Australia.
Butler K; Day C; Dietze P; Bruno R; Alati R; Burns L
J Subst Abuse Treat; 2015 Nov; 58():90-4. PubMed ID: 26117080
[TBL] [Abstract][Full Text] [Related]
10. Patient preferences for healthcare delivery through community pharmacy settings in the USA: A discrete choice study.
Feehan M; Walsh M; Godin J; Sundwall D; Munger MA
J Clin Pharm Ther; 2017 Dec; 42(6):738-749. PubMed ID: 28627110
[TBL] [Abstract][Full Text] [Related]
11. 'Standing Outside the Junkie Door'-service users' experiences of using community pharmacies to access treatment for opioid dependency.
Radley A; Melville K; Easton P; Williams B; Dillon JF
J Public Health (Oxf); 2017 Dec; 39(4):846-855. PubMed ID: 27915259
[TBL] [Abstract][Full Text] [Related]
12. Patient preferences for objective quality metrics during community pharmacy selection: A discrete choice experiment.
Patterson JA; Holdford DA; Harpe SE
Res Social Adm Pharm; 2019 Jun; 15(6):641-649. PubMed ID: 30143466
[TBL] [Abstract][Full Text] [Related]
13. Involving the public and other stakeholders in development and evaluation of a community pharmacy alcohol screening and brief advice service.
Krska J; Mackridge AJ
Public Health; 2014 Apr; 128(4):309-16. PubMed ID: 24713598
[TBL] [Abstract][Full Text] [Related]
14. The politics of place(ment): problematising the provision of hepatitis C treatment within opiate substitution clinics.
Rance J; Newland J; Hopwood M; Treloar C
Soc Sci Med; 2012 Jan; 74(2):245-53. PubMed ID: 22133583
[TBL] [Abstract][Full Text] [Related]
15. A quasi-experimental evaluation of dried blood spot testing through community pharmacies in the Tayside region of Scotland.
Radley A; Melville K; Tait J; Stephens B; Evans JMM; Dillon JF
Frontline Gastroenterol; 2017 Jul; 8(3):221-228. PubMed ID: 28839912
[TBL] [Abstract][Full Text] [Related]
16. Pharmacist's Demand for Optimal Primary Care Service Delivery in a Community Pharmacy: The OPTiPharm Study.
Munger MA; Walsh M; Godin J; Feehan M
Ann Pharmacother; 2017 Dec; 51(12):1069-1076. PubMed ID: 28737045
[TBL] [Abstract][Full Text] [Related]
17. Client and staff experiences of a co-located service for hepatitis C care in opioid substitution treatment settings in New South Wales, Australia.
Treloar C; Rance J; Grebely J; Dore GJ
Drug Alcohol Depend; 2013 Dec; 133(2):529-34. PubMed ID: 23932843
[TBL] [Abstract][Full Text] [Related]
18. How to build trustworthy hepatitis C services in an opioid treatment clinic? A qualitative study of clients and health workers in a co-located setting.
Treloar C; Rance J;
Int J Drug Policy; 2014 Sep; 25(5):865-70. PubMed ID: 24559604
[TBL] [Abstract][Full Text] [Related]
19. Patient awareness, willingness, and barriers to point-of-care hepatitis C screening in community pharmacy.
Brewer A; Hanna C; Eckmann L; Schadler A; Divine H
J Am Pharm Assoc (2003); 2018; 58(4S):S69-S72.e1. PubMed ID: 30006188
[TBL] [Abstract][Full Text] [Related]
20. Uptake and delivery of hepatitis C treatment in opiate substitution treatment: perceptions of clients and health professionals.
Treloar C; Newland J; Rance J; Hopwood M
J Viral Hepat; 2010 Dec; 17(12):839-44. PubMed ID: 20070504
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
